Start With the Three Facts That Decide the Discussion
A useful conversation about immunotherapy in China does not begin with the drug name. It begins with three facts the treating team needs: the exact tumour type and stage, the biomarker results that have already been tested, and the treatments already received, including whether the cancer progressed during or after them. Immunotherapy helps the immune system act against cancer, but whether it is appropriate depends on the cancer and an individual assessment. That assessment is specific, not general.
This is why a question such as "can I have immunotherapy in China?" is too broad to answer well. The same drug class can be a reasonable option in one cancer setting and inappropriate in another. A clinician needs to know what the cancer is, what it has done so far, and what the laboratory work shows before discussing benefit, risk or alternatives.
Before any appointment, prepare a short summary rather than a complete archive: diagnosis in one sentence, stage, key biomarker reports, a dated list of prior treatments and responses, current medicines, and the single question you most want answered. Ask the receiving team which documents it needs in full. A free initial case review can check whether this summary is complete enough to route, but it is not a diagnosis or a promise of acceptance.
Ask Whether Immunotherapy Is Appropriate for Your Diagnosis
The first clinical question is appropriateness, not availability. Ask directly: "For my tumour type, stage and biomarker profile, is immunotherapy an appropriate option, and on what evidence?" Then ask what the team would recommend if you did not receive it. A recommendation without a stated alternative is hard to weigh.
Ask which specific agent or regimen is being proposed and why that one rather than another. Immunotherapy is an umbrella term covering different mechanisms, and it is not the same as CAR-T cell therapy or other cellular treatments. If a cellular therapy is mentioned, treat it as a separate question with its own eligibility review, because review does not establish trial enrolment, transplant access or therapy availability.
Ask what the team expects the treatment to achieve in your situation: shrinkage, control, symptom relief, or something else. Ask what would count as benefit and what would count as failure, and at what point the plan would be reconsidered. These are reasonable questions, and a team that cannot answer them clearly is a reason to seek another opinion rather than to proceed.
Ask About Risks in Your Own Clinical Context
Immunotherapy carries its own risks, and these are not limited to logistics. Ask the treating clinician to explain the specific risks relevant to your cancer, your organs and your other conditions, and how those risks would be monitored. Ask what symptoms should prompt you to contact the team urgently, and who to contact at night or at a weekend.
Ask how pre-existing autoimmune disease, organ function, infection status or current medicines might change the risk calculation. Ask whether any of your current treatments would need to be adjusted, and who would make that decision. Do not change any medicine yourself on the basis of an article; that decision belongs to your prescribing clinician.
You are entitled to ask about evidence-based estimates of benefit and risk, including uncertainty. A responsible clinician can discuss what is known from studies and where the evidence is thin, without guaranteeing an individual result. If you are given a number, ask what population it came from and how closely that population resembles you.
Ask What Alternatives Exist and How They Compare
Alternatives depend on the cancer and prior treatment, so ask the team to list the realistic options it would consider: other systemic therapy, targeted therapy, radiotherapy, surgery, clinical trial participation, or best supportive care. Ask how each compares with immunotherapy in terms of expected benefit, burden and risk, and which the team would choose first and why.
Ask whether any option is time-sensitive. Some cancers behave differently if treatment is delayed, and that affects how much time you have to gather records or seek another opinion. If the team says a decision can wait, ask for how long and what would change that advice.
If you are considering care in China, ask whether the alternatives you are discussing are actually available for your diagnosis at the hospital you are approaching. Availability is a hospital-specific question, not something that can be assumed from a drug's approval elsewhere. Ask the named hospital to confirm in writing what it can offer for your case.
Ask How Monitoring Would Continue at Home
For an overseas patient, the practical question is often not the first dose but the follow-up. Ask how the treatment would be monitored, what tests would be needed and how often, and which of those could be done near home. Ask what the China team would need from your local clinician, and what it would send back.
Ask who would manage side effects once you have returned home, and how the two teams would communicate if something changed. Ask what would happen if the treatment needed to be stopped early, and what the plan would be then. These questions matter because a plan that only works while you are in China is not a complete plan.
Ask the hospital to explain its own arrangements for international patients, including how records are shared and how appointments are scheduled. Do not assume a particular scheduling or reporting practice applies; ask the specific provider what its process is and what it needs from you.
Prepare Your Questions and Take the Next Step
Write your questions down before the appointment and take notes during it. A short list works better than a long one. Ask the clinician to confirm suitability, alternatives and monitoring in plain terms, and ask what remains uncertain. If you do not understand an answer, say so and ask again.
One habit makes the rest easier: separate what you know from what you are asking. Put the confirmed diagnosis, stage, biomarker results and dated treatment history on one page, and your open questions on another. When a clinician answers, note whether the answer was a fact, an estimate or a judgement, because those carry different weight when you weigh the decision.
Ask who on the team owns each part of the plan. Suitability, the choice of regimen and the response to a side effect may sit with different people, and knowing who to contact for what prevents a question from stalling. If a question is outside a person's role, ask them to name the colleague who can answer it rather than accepting a general reply.
Ask what would make the team revisit the plan. A clear trigger, such as a scan result, a symptom or a laboratory value, tells you what the plan is waiting on and when the next real decision point falls. Without that, a plan can feel settled when it is only provisional.
Ask how a disagreement would be handled. If your local clinician reads the evidence differently, or you want a second opinion before committing, ask how the China team would receive that input and what records it would need. A team that welcomes the question is easier to work with than one that treats it as a challenge.
Keep the enquiry focused. A brief summary is enough to start, and you can share fuller records after first contact. An initial enquiry is free and does not require buying a proxy consultation. The hospital decides suitability, and no outcome is guaranteed.
If you would like help identifying the right next step, you can start with a short summary of the diagnosis, biomarkers, prior treatment and your main question. The team can check what is missing and suggest a relevant route, while clinical decisions remain with the treating hospital and licensed clinicians.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.